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Summary: Elimination kinetics of serum total and free prostate-specific antigen were studied for a ten days course
after radical retropubic prostatectomy on 11 patients suffering from organ confined prostate cancer. Samples were
taken before operation, immediately after finishing the operation and 1, 2, 3, 4, 5, 6 h after prostatectomy and then
once a day for the following ten days. The measurements were performed with AxSym assays from Abbott Laborato-
ries. The elimination of both total and free prostate-specific antigen followed a biphasic kinetics. In the fast phase,
the average of the individual elimination half-lives of total and free prostate-specific antigen amounted to 6.3 h
(SD = 6.1 h; range: 0.55 to 37.1 h) and 0.57 h (SD = 0.18 h; range: 0.22 to 0.89 h), respectively. In the slow phase,
total prostate-specific antigen disappeared with an average half-life of 85.6 h (SD = 11 h; range: 47.2 to 261.7 h)
and free prostate-specific antigen with an average half-life of 14.4 h (SD = 10.4 h; range: 2.4 to 30.3 h). These
results might be significant for the use of free and total prostate-specific antigen and its ratio as a diagnostic and
prognostic tool.
Introduction
Prostate-specific antigen is the most powerful serum
marker for the diagnosis of prostate cancer (1, 2). It is
used for screening, assessment of treatment response
and prediction of relapse. However, increased prostate-
specific antigen concentrations occur not only in patients
with adenocarcinoma of the prostate but also in case
of benign prostatic hyperplasia, inflammation and after
manipulation (1).
Recently, it has been found that prostate-specific antigen
exists in different molecular forms (3—6). Most of the
prostate-specific antigen is complexed to the protease
inhibitors ai-antichymotrypsin, a2-macroglobulin and
arantitrypsin. About 10—20% of the total prostate-spe-
cific antigen circulates as a free form in blood. Patients
with prostate cancer have a lower proportion of this free
form than patients with benign prostatic hyperplasia
(3—6). It has been suggested that the ratio of the free to
total prostate-specific antigen allows a better differentia-
tion between patients suffering from prostate cancer and
those with benign prostatic hyperplasia (7—9). The
reason for this phenomenon is not clear since little is
known about the metabolism of the various molecular
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forms of prostate-specific antigen. It has been suggested
that an increased synthesis of -antichymotrypsin oc-
curs in tumour cells. Thus, more free prostate-specific
antigen is complexed in tumour cells than in normal
cells and leads to these changes observed in serum (10).
Other authors believe that the changed glycation rate of
prostate-specific antigen found in dysplastic cells results
in characteristic differences of the elimination of pros-
tate-specific antigen from blood (11).
Whereas the clearance rates of total prostate-specific an-
tigen were intensively studied, scarce data exist on the
elimination kinetics of the different molecular forms
mentioned above (12-17). To get further insight into
this problem, it seems necessary to compare the elimina-
tion kinetics of free and total prostate-specific antigen.
Thus, this study was designed to determine the elimina-
tion kinetics of free and total prostate-specific antigen
following radical prostatectomy in patients with organ
confined prostate cancer.
Materials and Methods
Study material and blood sampling
The study approved by the ethical standards committee of the hos-
pital was performed on 11 men (55 to 71 years) undergoing radical
retropubic prostatectomy. The diagnosis of prostate cancer was
established histopathologically. The patients had no metastases
(pT2, T3, pNO, MO). During the study no patients received blood
or plasma infusions.
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Intravenous blood samples were taken according to the following
scheme: before operation; immediately after finishing the operation
(generally within the first 30 min); 1, 2, 3, 4, 5, 6 h after prostatec-
tomy and then once a day for the following ten days. Blood sam-
ples were centrifuged at 1500 g for 10 min after allowing the blood
to clot for l h at room temperature. The serum was frozen at
—80 °C within 2 hours after collection and was not thawed before
test performance.
Assays
AxSym test kits (Abbott Diagnostics, Abbott Park, IL, USA) were
used for measuring free and total prostate-specific antigen. These
assays are microparticle enzyme immunoassays. The sample is in-
cubated with microparticles coated with antibodies that bind a spe-
cific epitope either of total or free prostate-specific antigen. An
aliquot of the reaction mixture is automatically pipetted into a spe-
cial reaction cell where the microparticles bind irreversibly to a
glass fibre matrix. Unbound materials are removed by washing and
anti-prostate-specific antigen antibody labelled with alkaline phos-
phatase is added that binds to the antibody-antigen complex. The
unbound components are removed, the substrate 4-methylumbellif-
eryl phosphate is added and the fluorescent 4-methylumbelliferone
which is released is measured on the immunoassay analyser Ax-
Sym.
Total and free prostate-specific antigen concentrations were simul-
taneously measured as a single run for each patient. Ten separate
runs were performed for the samples of the 11 patients. Each run
was checked by two control sera for total prostate-specific antigen
(4.01 and 15.4 g/l) and three control sera for free prostate-specific
antigen (0.39; 0.96; 6.85 g/l). The between-run precisions calcu-
lated from these ten runs were between 2.6 and 4.7%. The within-
run precisions (n = 12) were between 2.1 and 3.5%. The lower
detection limits were calculated on the basis of the means and 3 SD
of 10 replicate intra-assay determinations of the zero calibrators of
the total and free prostate-specific antigen assays. The lower detec-
tion limits were 0.096 g/l for total and 0.005 g/l for free prostate-
specific antigen.
Calculations
The evaluation of the elimination kinetics of free and total prostate-
specific antigen was performed by using the equation
prostate-specific antigen, = a~k | ' ' + b~kz l
The data of free and total prostate-specific antigen clearance were
fitted by applying a non-linear regression procedure (18). Statisti-
cal calculations were performed by the statistical package Stat-
graphics, version 5.01 (Statistical Graphics, Rockville, USA). The
t-test according to Student with paired data was used.
Results and Discussion
Serum concentrations of total and free prostate-specific
antigen were measured before and after radical retropu-
bic prostatectomy in 11 patients. The percentage ratios
of free to total prostate-specific antigen before prostatec-
tomy were < 15% in all patients except one patient with
18% (tab. 1). These results confirmed our previous data
that the ratio of free to total prostate-specific antigen
was lower in patients with prostate cancer than in heal-
thy men or patients with benign prostatic hyperplasia
(7). The concentrations found before prostatectomy, 30
min after operation as the first point after the prostate
was removed and then 10 days afterwards demonstrated
that the concentrations varied in a broad range (tab. 1).
By surgical intervention, concentrations of free, but not
of total prostate-specific antigen, were increased com-
pared to the data obtained before prostatectomy. Both
forms decreased rapidly afterwards. However, the ratio
of free to total prostate-specific antigen at day 10 after
prostatectomy compared to the initial value showed that
the free form was more rapidly eliminated. Conse-
quently, the percentage ratio of free to total prostate-
specific antigen decreased about 10-fold, from 10.4% to
0.93%. At the end of this ten day follow-up study, the
concentrations of both total and free prostate-specific
antigen were still higher than the detection limits of the
assays for total and free prostate-specific antigen (0.096
and 0.005 g/l, respectively). Thus, all data concentra-
tions measured could be used for the calculation of elim-
ination kinetics.
The calculations of clearance rates of prostate-specific
antigen were performed with normalized data. For the
purpose of normalizing the varying concentrations of
prostate-specific antigen, the concentration of prostate-
specific antigen of each patient measured in the serum
sample collected within 30 min after finishing the opera-
tion was set at 1.0. All other concentrations of prostate-
specific antigen of the respective patient were calculated
as fractiles of that initial value. The clearance of both
total and free prostate-specific antigen was characterized
by biexponential kinetics (fig. 1). A fast phase of elimi-
nation was found during the first 8 h after prostatectomy
followed by a slow phase. In the fast phase, the means
of the 11 individual elimination half-lives of total and
free prostate-specific antigen amounted to 6.3 h (SD
= 6.1 h; range: 0.55 to 37.1h) and to 0.57 h (SD
= 0.18 h; range: 0.22 to 0.89 h), respectively. In the
slow phase, total prostate-specific antigen disappeared
with an average half-life of 85.6 h (SD = 11 h; range:
47.2 to 261.7 h) and free prostate-specific antigen with
an average half-life of 14.4 h (SD = 10.4 h; range: 2.4
to 30.3 h).
There are several studies in the literature regarding the
disappearance rate of total prostate-specific antigen after
radical prostatectomy (12—17). Both monophasic and
biphasic patterns have been described. Oesterling et al.
(14) and Semjonow et al. (15, 19, 20) both described a
monoexponential elimination kinetics of total prostate-
specific antigen and determined a half-life of 75.6 h and
38.4 h, respectively. Stamey et al. (13) and Van Straalen
et al. (17) described a two phase elimination with a
shorter half-life of 12.6 h and 1.63 h, respectively and a
longer half-life of 52.8 h and 111 h, respectively. Our
half-life data amounting to 6.3 h and 85.6 h were in this
range. It was assumed that the delay of the first serum
collection after surgery, for example 48 h as done by
Oesterling et al. (14) resulted in missing the fast phase
of elimination (21). Thus, the study design and espe-
cially the sampling apparently affect the form of the
elimination kinetics (22). Our study design considered
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Data are arithmetic mean values ± 1 SD of 11 patients. * = p < 0.05; ** = p < 0.01; p < 0.001 versus values before
operation (t-test with paired data).
that suggestion by measuring samples obtained in short-
term intervals after prostatectomy. Thus, the two phases
of elimination both for total and free prostate-specific
antigen observed in our study stronlgy support the as-
sumption that sampling is important for a correct evalua-
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Fig. l Elimination of serum total prostate-specific antigen from
blood following radical retropubic prostatectomy. The curves rep-
resent mean values ± 1 SD from 11 patients expressed as fractiles
of the initial concentration measured within 30 min after finishing
the operation. The values obtained during the first 24 h after prosta-
tectomy are presented in (a) and the values between the first and
10th day after prostatectomy in (b).
Studies on eliminiation kinetics have suggested that the
half-life determination is a more powerful predictive
tool for a relapse than the evidence of "undetectable"
concentrations of prostate-specific antigen (19). For ex-
ample, relapse-free patients had a shorter half-life of the
elimination of prostate-specific antigen than patients
with recurrent disease during a follow-up of two years
after prostatectomy. It might be that the determination
of the half-life of free prostate-specific antigen has a
better clinical validity than the determination of the cor-
responding half-life of total prostate-specific antigen
(22).
It has been suggested that the biphasic elimination
pattern is caused by the occurrence and biochemical
characteristics of the molecular forms of prostate-spe-
cific antigen (23). The occurrence of various forms of
prostate-specific antigen was briefly outlined in the in-
troduction. About 80% of serum prostate-specific anti-
gen is complexed to the protease inhibitors di-antichy-
motrypsin, apantitrypsin and a2-macroglobulm. The
rest of serum prostate-specific antigen occurs as free,
non-complexed form. The complex of ai-antichymo-
trypsin with prostate-specific antigen is the major form
of these complexes, whereas the prostate-specific anti-
gen bound to the other two inhibitors is only found in
small concentrations (5, 24). However, little is known
about the metabolism of prostate-specific antigen and its
forms. As reliable methods for determining the com-
plexes of prostate-specific antigen have not yet been
available, the conclusions about the metabolism must
rely upon measurements of total and free prostate-spe-
cific antigen. Our data show that free prostate-specific
antigen is similarly eliminated as total prostate-specific
antigen by a biphasic kinetics. However, the half-lives
of the fast and the slow phases are clearly lower than
those of the total prostate-specific antigen. After our in-
vestigations were finished, the results of two studies on
the elimination kinetics of free prostate-specific antigen
became available (22, 23). The authors also described a
biphasic elimination pattern and calculated half-lives for
the fast phase of 1.2 h and 1.9h, respectively and for
the slow phase of 22 h and 6 h, respectively. These re-
sults are in general agreement with our mean half-lives
of 0.57 h and 14.4 h.
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Fig. 2 Elimination of serum free prostate-specific antigen from
blood following radical retropubic prostatectomy. The curves rep-
resent mean values ± 1 SD from 11 patients expressed as fractiles
of the initial concentration measured within 30 min after finishing
the operation. The values obtained during the first 24 h after prosta-
tectomy are presented in (a) and the values between the first and
10th day after prostatectomy in (b).
The dramatic decrease of the free prostate-specific anti-
gen in the early phase of elimination might be the result
of its rapid binding to a2-macroglobulin and/or aranti-
chymotrypsin (4, 25). The complexation with a2-macro-
globulin cannot be ascertained by common irnmuno-
assays for prostate-specific antigen since a2-macroglob-
ulin encapsulates all epitopes of prostate-specific anti-
gen (25). The in vitro rate of complex formation of
prostate-specific antigen with a2-macroglobulin was
more pronounced than that with ai-antichymotrypsin
(4). In addition, there are special "nicked" forms of pros-
tate-specific antigen containing multiple proteolytic
cleavages that lose the binding affinity to arantichymo-
trypsin (25). That could explain the occurrence of free
prostate-specific antigen in serum despite a 104 to 105-
fold excess of cii-antichymotrypsin in the blood com-
pared to prostate-specific antigen (24). Thus, other pro-
cesses of elimination of the free form of prostate-spe-
cific antigen have to be considered. The slower phase of
the biphasic elimination of free prostate-specific antigen
could result. Free prostate-specific antigen with a rela-
tive molecular mass of about 28 000 corresponds to the
low molecular mass proteins that are generally catabo-
lized and eliminated by the kidney (26). Agha et al. (27)
tried to identify the main site where prostate-specific
antigen is metabolized. This evaluation was based on
selective arterial and venous sampling and the analysis
of concentration changes across the renal, hepatic, pul-
monary and pelvic circulation. The kidneys and lungs
had no significant role in the elimination of prostate-
specific antigen. The non-significant role of the kidney
in the clearance rate of prostate-specific antigen was
supported by unchanged serum concentrations of pros-
tate-specific antigen found in men with chronic renal
failure (28). The prostate-specific antigen complexed
with ai-antichymotrypsin or a2-macroglobulin is far too
large to be filtered through the glomerular membrane.
The liver was the most likely site of prostate-specific
antigen metabolism (27). Lilja et al. (4) also speculated
that the liver could be the main site of prostate-specific
antigen metabolism. That could be taken into consider-
ation both for free and complexed prostate-specific anti-
gen. Different glycoated variants of prostate-specific an-
tigen were found by the chromatofocusing technique
(11). The heterogeneity of prostate-specific antigen
could influence the liver uptake of these forms due to
the involvement of the asialo-glycoprotein receptor in
this process. Similar effects were described for the elim-
ination of circulating γ-glutamyltransferase (29). In ad-
dition to the effect of this general receptor, the involve-
ment of special receptors on liver cells, which can elimi-
nate the complex between the serine protease and its
inhibitors (30, 31), could be significant. It was suggested
that these receptors might be responsible for the hepatic
uptake of the complex of prostate-specific antigen with
ai-antichymotrypsin (27).
In conclusion, our results have both biochemical and
clinical significance. First, the findings that both free
and complexed forms of prostate-specific antigen are
eliminated by a biphasic kinetics with different half-
lives improve our understanding of the metabolism of
prostate-specific antigen. However, the exact mecha-
nisms have to be elucidated. Secondly, the longer half-
life of total prostate-specific antigen compared with
the free form indicates that after prostatic manipulation
(e.g., digital rectal examination, biopsy etc.) about
three weeks (17) have to pass in order to reach the
baseline level of the free and total prostate-specific
antigen. Only then might the ratio of free to total
prostate-specific antigen be useful as a discriminator
between patients with prostate cancer and benign pros-
tatic hyperplasia.
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